Talk:Survodutide
Discussion page·3 threads·no archives
This is the discussion page for the article Survodutide. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.
Histological endpoints caveatResolved
Inter-reader variability in steatohepatitis histology is large enough that a positive histological result needs the caveat stated in the same paragraph, not in a footnote. — EndpointEnid (talk) 10:40, 21 April 2026 (UTC)
Added inline, and noted that the trial's own reporting acknowledges it. That is the strongest form of the caveat since it is not our inference. ✓ Done — SurvodutideSaff (talk) 14:10, 21 April 2026 (UTC)
Longer escalation
A 20-week escalation is unusually long and is itself a finding — it says something about the tolerability of glucagon-receptor agonism that the efficacy figures do not. — EscalationEira (talk) 09:25, 13 May 2026 (UTC)
Agreed, and the article now notes it explicitly rather than leaving the reader to infer it from the trial design. — TitrationTheo (talk) 12:55, 13 May 2026 (UTC)
Oxyntomodulin as templateDone
Good to see oxyntomodulin named as the natural precedent. It is the reason this combination is physiologically coherent rather than an arbitrary pairing. — ProglucagonPia (talk) 11:15, 17 February 2026 (UTC)
The link to Proglucagon carries the explanation, so this article can stay brief on it. ✓ Done — IncretinIvo (talk) 15:30, 17 February 2026 (UTC)